2-溴-1-(4-甲基-1H-咪唑-5-基)乙酮 | 82982-54-5

• 分子结构分类: 有机化合物 - 有机氧化合物
• 中文名称: 2-溴-1-(4-甲基-1H-咪唑-5-基)乙酮
• 英文名称: 2-bromo-1-(5-methyl-1(3)H-imidazol-4-yl)-ethanone
• 英文别名: 2-Brom-1-(5-methyl-1(3)H-imidazol-4-yl)-aethanon；2-Bromo-1-(5-methyl-1H-imidazol-4-YL)-ethanone；2-bromo-1-(5-methyl-1H-imidazol-4-yl)ethanone
• CAS: 82982-54-5
• 化学式: C₆H₇BrN₂O
• 分子量: 203.038
• InChiKey: NHZTZQDWMOWTJF-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.3
• 重原子数：
  10
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  45.8
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  2-溴-1-(4-甲基-1H-咪唑-5-基)乙酮 在 sodium amalgam 、 水 、 溶剂黄146 作用下， 生成 2-amino-1-(5-methyl-1(3)H-imidazol-4-yl)-ethanol
  参考文献：
  名称：

  Tamamushi, Yakugaku Zasshi/Journal of the Pharmaceutical Society of Japan, 1940, vol. 60, p. 184,188; dtsch. Ref. S. 92, 95

  摘要：

  DOI：
• 作为产物：
  描述：

  2,3,4-戊三酮肟 (6ci,7ci,8ci,9ci) 在 盐酸 、 palladium on activated charcoal 、 溴 、 硝酸 、 溶剂黄146 作用下， 生成 2-溴-1-(4-甲基-1H-咪唑-5-基)乙酮
  参考文献：
  名称：

  Tamamushi; Nagasawa, Yakugaku Zasshi/Journal of the Pharmaceutical Society of Japan, 1940, vol. 60, p. 127,131

  摘要：

  DOI：

文献信息

• 2-Guanidino-4-heteroarylthiazoles
  申请人：Pfizer Inc.

  公开号：US04374843A1

  公开（公告）日：1983-02-22

  A series of 2-guanidino-4-heteroarylthiazoles, wherein the heteroaryl substituent is selected from thiazolyl, triazolyl, imidazolyl, and 2-alkyl, 2-amino and 2-carboxamido derivatives thereof, are disclosed. The novel compounds have activity as antisecretory agents and histamine H.sub.2 antagonists and are useful for the treatment of gastric hyperacidity and peptic ulcers. Also disclosed are pharmaceutical compositions containing the novel compounds of this invention and a method of using the compounds in the treatment of gastric hyperacidity and peptic ulcers. Novel intermediates useful in the preparation of the novel antisecretory compounds are also described.

  本发明揭示了一系列2-胍基-4-杂环芳基噻唑，其中杂环芳基取代基选自噻唑基、三唑基、咪唑基以及其2-烷基、2-氨基和2-羧酰胺衍生物。这些新颖的化合物具有抗分泌作用和组胺H.sub.2拮抗剂活性，可用于治疗胃酸过多和消化性溃疡。还揭示了含有本发明新化合物的药物组合物以及使用这些化合物治疗胃酸过多和消化性溃疡的方法。还描述了在制备新型抗分泌化合物中有用的新颖中间体。
• Haloacetyl imidazoles
  申请人：Pfizer Inc.

  公开号：US04452987A1

  公开（公告）日：1984-06-05

  A series of 2-guanidino-4-heteroarylthiazoles, wherein the heteroaryl substituent is selected from thiazolyl, triazolyl, imidazolyl, and 2-alkyl, 2-amino and 2-carboxamido derivatives thereof, are disclosed. The novel compounds have activity as antisecretory agents and histamine H.sub.2 antagonists and are useful for the treatment of gastric hyperacidity and peptic ulcers. Also disclosed are pharmaceutical compositions containing the novel compounds of this invention and a method of using the compounds in the treatment of gastric hyperacidity and peptic ulcers. Novel intermediates useful in the preparation of the novel antisecretory compounds are also described.

  本发明揭示了一系列2-胍基-4-杂环芳基噻唑化合物，其中杂环芳基取代基选择自噻唑基、三唑基、咪唑基和2-烷基、2-氨基和2-羧酰胺衍生物。这些新型化合物具有抗分泌作用和组胺H.sub.2拮抗剂作用，适用于治疗胃酸过多和消化性溃疡。本发明还揭示了含有这些新型化合物的制药组合物以及使用这些化合物治疗胃酸过多和消化性溃疡的方法。还描述了制备新型抗分泌化合物的新型中间体。
• Compounds, pharmaceutical compositions, and methods for inhibiting cyclin-dependent kinases
  申请人：——

  公开号：US20030220326A1

  公开（公告）日：2003-11-27

  Pharmaceutical compositions containing effective amounts of CDK-inhibiting diaminothiazole compounds of the following formula (where R 1 and R 2 are as defined in the specification) or their salts, or prodrugs or active metabolites of such compounds or salts, are useful for treating disorders and diseases such as cancer: 1 In preferred embodiments, R 1 and R 2 are independently unsubstituted or substituted carbocyclic or heterocyclic aryl ring structures. Compounds where R 2 is ortho-substituted aryl are especially potent inhibitors of CDKs such as CDK4.

  含有以下公式中CDK抑制二氨基噻唑化合物的有效量的药物组合物（其中R1和R2如规范所定义）或其盐，或这些化合物或盐的前药或活性代谢物，可用于治疗癌症等疾病和疾病。在首选实施例中，R1和R2分别是未取代或取代的碳环或杂环芳香环结构。其中R2为邻位取代芳香族的化合物特别是CDKs如CDK4的有效抑制剂。
• 2-guanidino-4-heteroarylthiazoles
  申请人：Pfizer Inc.

  公开号：US04590299A1

  公开（公告）日：1986-05-20

  A series of 2-guanidino-4-heteroarylthiazoles, wherein the heteroaryl substituent is selected from thiazolyl, triazolyl, imidazolyl, and 2-alkyl, 2-amino and 2-carboxamido derivatives thereof, are disclosed. The novel compounds have activity as antisecretory agents and histamine H.sub.2 antagonists and are useful for the treatment of gastric hyperacidity and peptic ulcers. Also disclosed are pharmaceutical compositions containing the novel compounds of this invention and a method of using the compounds in the treatment of gastric hyperacidity and peptic ulcers. Novel intermediates useful in the preparation of the novel antisecretory compounds are also described.

  本发明揭示了一系列2-胍基-4-杂环芳基噻唑化合物，其中杂环芳基取代基选自噻唑基、三唑基、咪唑基和2-烷基、2-氨基和2-羧酰胺衍生物。这些新型化合物具有抗分泌作用和组胺H.sub.2 拮抗剂活性，可用于治疗胃酸过多和消化性溃疡。本发明还揭示了含有这些新型化合物的制药组合物以及使用这些化合物治疗胃酸过多和消化性溃疡的方法。还描述了制备新型抗分泌化合物的新型中间体。
• 2-Guanidino-4-heteroarylthiazoles and pharmaceutical compositions containing them
  申请人：PFIZER INC.

  公开号：EP0050458A2

  公开（公告）日：1982-04-28

  A series of 2-guanidino-4-heteroarylthiazoles of the formula: and the pharmaceutically acceptable acid addition salts thereof, wherein X is S or NH; Y is CH, C.CH3 or N; R is hydrogen, hydroxymethyl, alkyl of 1 to 6 carbon atoms, -(CH2)nAr, -NH2, -NHR1 or -NHCOR1, wherein R1 is alkyl of 1 to 6 carbon atoms or -(CH2)mAr; n is an integer from 2 to 4; m is zero or an integer from 1 to 4; Ar is phenyl or phenyl monosubstituted with chloro, bromo, fluoro, alkyl of 1 to 3 carbon atoms or alkoxy of 1 to 3 carbon atoms; provided that when Y is N, X is NH and m is other than zero; and when X is S, R is other than hydroxymethyl, alkyl, or -(CH2)nAr; and pharmaceutical compositions containing them. The compounds are useful in the prevention or treatment of gastric hyperacidit y and peptic ulcers. Also included are certain intermediates useful in the preparation of the thiazoles.

  一系列式中的 2-胍基-4-杂芳基噻唑： 及其药学上可接受的酸加成盐、 其中 X 是 S 或 NH；Y 是 CH、C.CH3或N；R是氢、羟甲基、1～6个碳原子的烷基、-(CH2)nAr、-NH2、-NHR1或-NHCOR1，其中R1是1～6个碳原子的烷基或-(CH2)mAr；n是2～4的整数；m是零或1～4的整数；Ar是苯基或被氯、溴、氟、1至3个碳原子的烷基或1至3个碳原子的烷氧基单取代的苯基；条件是当Y是N时，X是NH，m不是零；当X是S时，R不是羟甲基、烷基或-(CH2)nAr；以及含有它们的药物组合物。这些化合物可用于预防或治疗胃酸过多和消化性溃疡。此外，还包括某些用于制备噻唑类化合物的中间体。